Hypokalemia in HIV patients on tenofovir

AIDS

Volumn 20, Issue 12, 2006, Pages 1671-1673

  Cirino, Christopher M ^a   Kan, Virginia L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; RITONAVIR; TENOFOVIR;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION;

ADENINE; ADOLESCENT; ADULT; BODY WEIGHT; CHILD; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPOKALEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; TIME FACTORS;

EID: 33746744419     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000238416.05819.09     Document Type: Article

References (8)

1. Viread (tenofovir disoproxil fumarate) package insert. Foster City, CA: Gilead Sciences; March 2006.
2. Fine DM. Editorial comment: tenofovir nephrotoxicity - vigilance required. AIDS Reader 2005; 15:362-363.
3. Nelson M, Cooper D, Schooley R, Katlama C, Montaner J, Curtis S, et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. In: Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, 5-9 February 2006 [A781].
4. Zimmerman AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
5. Food and Drug Administration. Viread: NDA 21-346/S-006. Rockville, MD: Food and Drug Administration; 2003.
6. Peyriere H, Reynes J, Rouanet I, Daniel N, deBoever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
7. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004; 18:351-352.
8. Galland JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.